This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_SECONDARY_NAS_EXALLC for full statistics.
Secondary malignant neoplasm of other and unspecified sites
C3_SECONDARY_NAS
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
443 |
4. Check minimum number of eventsNone |
443 |
5. Include endpointsNone |
443 |
6. Filter based on genotype QC (FinnGen only) |
443 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Secondary malignant neoplasm of other and unspecified sites
based on the number of shared cases.
Similar with more cases:
- Secondary uncertain malignant neoplasm
- Secondary malignant neoplasm of other and unspecified sites, excluding all cancers (controls excluding all cancers)
- Secondary uncertain malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 443 | 190 | 253 |
| Unadjusted period prevalence (%) | 0.09 | 0.06 | 0.11 |
| Median age at first event (years) | 72.44 | 70.07 | 74.23 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 324
- Matched controls
- 3237
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
85.3
162.1
177
45
H02AB02
ATC
dexamethasone; systemic
30.1
142.2
214
196
WF049
NOMESCO Finland
Radiotherapy of metastasis
50.9
119.4
144
50
N02AA05
ATC
oxycodone; systemic
16.8
108.6
217
349
A03FA01
ATC
metoclopramide; systemic, rectal
16.2
108.1
228
413
Z51.5
ICD-10 Finland
Palliative care
25.2
107.1
161
122
C79.3
ICD-10 Finland
Secondary malignant neoplasm of brain and cerebral meninges
+∞
105.0
95
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
74.3
104.1
116
24
130
Kela drug reimbursment
Malignant tumour
18.4
99.3
173
190
JN4BD
NOMESCO Finland
Extensive body CT
16.7
98.5
182
230
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
79.8
71.5
79
13
A04AA02
ATC
granisetron; systemic, transdermal
17.2
71.1
120
107
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
7.4
60.4
215
683
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
19.3
59.6
94
67
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
19.1
55.7
88
62
XX3DW
NOMESCO Finland
Time consuming IT work
9.2
52.2
124
205
M05BX04
ATC
denosumab; parenteral
14.1
50.0
90
86
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
13.5
42.5
77
73
JN4CD
NOMESCO Finland
Very extensive body CT
11.1
35.7
71
80
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
24.4
35.2
50
24
A04AA01
ATC
ondansetron; systemic, rectal
10.5
35.1
72
86
WF004
NOMESCO Finland
Palliative radiotherapy
25.9
32.4
45
20
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
8.7
29.5
67
94
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.9
29.5
222
1153
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
24.5
29.1
41
19
L01BC06
ATC
capecitabine; oral
11.8
29.1
55
55
NK6AN
NOMESCO Finland
Total body bone isotope imaging
11.6
25.8
49
49
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
45.3
24.0
29
7
WZC30
NOMESCO Finland
Teaching
4.5
22.8
93
268
WW500
NOMESCO Finland
Blood transfusion
8.8
22.3
49
64
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
22.0
22.2
32
16
AA1BD
NOMESCO Finland
Extensive CT of head and brain
11.6
21.8
41
40
A04AD12
ATC
aprepitant; systemic
15.5
21.4
35
25
163
Kela drug reimbursment
Abiraterone and enzalutamide
23.5
21.2
30
14
L02BA03
ATC
fulvestrant; parenteral
117.6
20.8
22
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.4
20.3
83
237
A02BC02
ATC
pantoprazole; systemic
3.3
20.0
252
1664
192
Kela drug reimbursment
Fulvestrant
111.9
19.8
21
*
115
Kela drug reimbursment
Breast cancer
6.3
19.0
53
98
L03AA13
ATC
pegfilgrastim; parenteral
8.9
19.0
41
52
L02BB04
ATC
enzalutamide; oral
25.5
19.0
26
11
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.5
18.6
72
194
C34.1
ICD-10 Finland
Malignant neoplasm: Upper lobe, bronchus or lung
17.9
18.2
28
17
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.0
18.2
62
146
L02BG04
ATC
letrozole; oral
7.5
17.5
42
63
C79.31
ICD-10 Finland
Secondary malignant tumor of the cerebellum
67.0
16.9
19
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
8.9
16.8
36
45
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
19.2
16.7
25
14
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.8
16.7
147
736
ZX080
NOMESCO Finland
Image guided radiotherapy
12.1
16.6
30
27
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
17.9
16.4
25
15
ZX090
NOMESCO Finland
Other technic of radiotherapy
9.1
16.2
34
41
A06AH03
ATC
naloxegol; oral
15.6
16.1
26
18
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
5.8
16.1
47
92
ZX070
NOMESCO Finland
Intensity modified radiotherapy
10.3
15.8
31
33
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
13.3
15.7
27
22
116
Kela drug reimbursment
Prostate cancer
4.6
15.5
57
144
L01CA04
ATC
vinorelbine; systemic
21.3
15.3
22
11
TPX10
NOMESCO Finland
Implantation of vascular injection port
9.9
15.1
30
33
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
17.6
15.0
23
14
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
9.1
14.9
31
37
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
20.3
14.4
21
11
B01AB10
ATC
tinzaparin; parenteral
4.8
14.4
50
119
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
8.9
13.3
28
34
L02AE02
ATC
leuprorelin; implant, parenteral
5.0
13.2
43
96
ZX120
NOMESCO Finland
Intravenous
3.9
13.1
57
169
D70.82
ICD-10 Finland
Drug-induced neutropenia
13.0
12.8
22
18
X76
ICPC
Malignant neoplasm breast female
12.4
12.0
21
18
C50.81
ICD-10 Finland
Overall malignant tumor of the mammary gland, ductal tumor
15.4
11.9
19
13
L02BA01
ATC
tamoxifen; oral
6.6
11.8
30
49
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
17.2
11.8
18
11
JN4AD
NOMESCO Finland
Body CT examination
3.7
11.8
53
161
R83
ICPC
Respiratory infection other
0.0
11.8
*
277
C50.4
ICD-10 Finland
Malignant neoplasm: Upper-outer quadrant of breast
31.3
11.7
15
5
A79
ICPC
Malignancy NOS
10.6
11.7
22
22
L02BX03
ATC
abiraterone; oral
23.9
11.7
16
7
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
6.5
11.3
29
48
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
13.4
11.3
19
15
L02AE03
ATC
goserelin; implant
10.6
11.2
21
21
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
11.1
43
114
C50.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of breast
44.9
11.0
13
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
5.3
10.9
33
68
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.2
10.7
33
69
L02BB03
ATC
bicalutamide; oral
5.2
10.7
33
69
J01MA12
ATC
levofloxacin; systemic
2.5
10.7
96
461
C79.39
ICD-10 Finland
Secondary malignant tumor of the meninges, ventricle or other part of the brain
113.5
10.5
11
*
C50.2
ICD-10 Finland
Malignant neoplasm: Upper-inner quadrant of breast
113.5
10.5
11
*
B01AB05
ATC
enoxaparin; parenteral
2.3
10.4
130
738
HA1AA
NOMESCO Finland
X-ray mammography
4.4
10.2
37
92
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
10.2
66
261
C34.3
ICD-10 Finland
Malignant neoplasm: Lower lobe, bronchus or lung
12.7
10.0
17
14
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
10.0
9.9
19
20
L17
ICPC
Foot/toe symptom/complaint
0.3
9.9
17
577
8140/3-C34.1
ICD-O-3
Adenocarcinoma, NOS, of upper lobe, lung
27.0
9.9
13
5
8000/3-C80.9
ICD-O-3
Neoplasm, malignant of unknown primary site
56.7
9.7
11
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
5.5
9.6
28
55
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.5
9.6
83
386
N02BE01
ATC
paracetamol; systemic, rectal
2.9
9.5
290
2425
R50.9
ICD-10 Finland
Fever, unspecified
2.8
9.5
67
277
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.1
9.5
54
196
HAC20
NOMESCO Finland
Total mastectomy
6.1
9.4
25
44
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
4.6
9.3
32
76
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
9.1
46
153
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
9.1
109
599
WVC10
NOMESCO Finland
Subcutaneous infusion of drugs
37.8
9.1
11
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
5.4
9.0
26
51
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
6.7
8.9
22
35
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.5
8.9
80
381
Y77
ICPC
Malignant neoplasm prostate
4.8
8.6
28
63
1501
Kela drug reimbursment
Palbociclib
28.4
8.5
11
*
8140/3-C34.9
ICD-O-3
Adenocarcinoma, NOS, of lung, NOS
28.4
8.5
11
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
6.1
8.5
22
38
Z25.8
ICD-10 Finland
Need for immunization against other specified single viral diseases
0.0
8.4
*
203
NF3AA
NOMESCO Finland
Femur X-ray examination
6.8
8.3
20
31
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
7.9
8.3
18
24
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
15.0
8.3
13
9
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.0
8.2
48
177
WX302
NOMESCO Finland
Thoracal epidural anesthesy
3.7
8.2
35
102
C80.0
ICD-10 Finland
Malignant neoplasm, primary site unknown, so stated
34.3
8.1
10
*
L02BX02
ATC
degarelix; parenteral
10.4
8.1
15
15
N02AX02
ATC
tramadol; systemic, rectal
2.0
8.1
158
1052
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
2.6
8.0
61
263
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.7
7.9
55
225
C34.9
ICD-10 Finland
Malignant neoplasm: Bronchus or lung, unspecified
11.2
7.9
14
13
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.4
7.7
74
361
N03AX14
ATC
levetiracetam; systemic
6.4
7.7
19
31
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
12.2
7.6
13
11
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
9.2
7.6
15
17
L01XE33
ATC
[U] palbociclib; oral
25.7
7.6
10
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
25.7
7.6
10
*
C43.5
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of trunk
25.7
7.6
10
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
4.0
7.6
29
77
N03AX16
ATC
pregabalin; oral
2.2
7.5
92
501
SPAT1254
SPAT
Administration of medicine
2.4
7.4
70
339
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
11.2
7.4
13
12
C79.2
ICD-10 Finland
Secondary malignant neoplasm of skin
+∞
7.3
7
*
C20
ICD-10 Finland
Malignant neoplasm of rectum
30.7
7.2
9
*
A06AD11
ATC
lactulose; oral
2.3
7.1
71
354
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
10.4
7.1
13
13
C61
ICD-10 Finland
Malignant neoplasm of prostate
2.4
7.1
61
281
C50.99
ICD-10 Finland
Breast, unspecified
6.6
7.0
17
27
ZX112
NOMESCO Finland
Subcutaneous
6.1
7.0
18
31
TGD00
NOMESCO Finland
Needle biopsy of lung
14.2
6.9
11
8
C34.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bronchus and lung
14.2
6.9
11
8
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.1
6.9
*
223
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
5.5
6.9
19
36
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
11.3
6.8
12
11
L03AA02
ATC
filgrastim; parenteral
5.1
6.8
20
41
180
Kela drug reimbursment
Interferon alfa
40.9
6.8
8
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.6
6.7
29
86
C34.32
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung adenocarcinoma
23.1
6.7
9
*
L01CB01
ATC
etoposide; systemic
12.6
6.6
11
9
L02BG06
ATC
exemestane; oral
9.0
6.6
13
15
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
10.3
6.6
12
12
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
10.3
6.6
12
12
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
6.4
104
629
JN4DD
NOMESCO Finland
Scout CT scan of torso
71.2
6.4
7
*
L01XE23
ATC
[U] dabrafenib; oral
71.2
6.4
7
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
8.4
6.4
13
16
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.3
6.4
30
96
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
11.3
6.3
11
10
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
18.4
6.3
9
5
159
Kela drug reimbursment
Pazopanib
+∞
6.3
6
*
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
27.2
6.3
8
*
J94.8
ICD-10 Finland
Other specified pleural conditions
6.0
6.2
16
28
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
6.1
81
453
WW200
SPAT
NA
0.0
6.1
*
153
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
12.8
6.1
10
8
WF099
NOMESCO Finland
Other radiotherapy
12.8
6.1
10
8
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
0.1
6.1
*
179
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
10.3
6.1
11
11
AA1AD
NOMESCO Finland
CT of head and brain
2.0
6.0
95
568
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
165
473
4.97
55.04
4.9
4.5
114.7
29.2
ug/l
1.26
153
405
352
2014
4.64
41.40
14.9
6.8
10.3
11.8
umol/l
1.19
346
1905
168
650
3.55
34.68
5.0
3.4
0.8
0.8
mmol/l
0.49
162
611
330
1951
3.71
33.49
10.2
7.1
1.2
1.2
mmol/l
0.23
231
1645
343
2106
3.79
32.17
17.4
9.2
4.8
4.1
e9/l
3.38
329
1851
305
1791
3.26
29.73
8.1
6.2
1.2
1.2
mmol/l
0.43
293
1602
40
56
7.75
27.58
4.5
2.9
64.9
58.6
%
1.42
40
56
233
3384
0.34
26.74
4.6
6.5
43.9
40.8
mmol/mol
0.85
193
3109
248
3476
0.35
25.39
2.9
4.7
1.4
1.5
mmol/l
0.60
203
3156
263
3586
0.34
25.38
3.0
5.4
2.7
2.6
mmol/l
0.47
211
3255
37
53
7.53
24.97
4.0
2.3
4.3
4.9
e9/l
0.53
37
53
254
3503
0.36
24.25
2.9
4.8
4.5
4.5
mmol/l
0.32
209
3206
66
1767
0.26
24.15
1.9
2.4
—
—
—
0
0
36
64
6.03
19.78
1.2
1.9
—
—
—
0
0
106
422
2.99
19.52
6.3
3.6
—
—
—
0
0
42
91
4.99
18.62
1.2
1.8
—
—
—
0
0
250
3358
0.41
17.90
2.8
4.2
1.3
1.3
mmol/l
0.96
205
3026
40
90
4.79
16.95
1.2
1.8
—
—
—
0
0
208
1224
2.32
16.56
2.9
2.5
50.7
57.0
u/l
1.22
199
1131
321
2281
2.48
16.30
6.1
5.0
6.8
6.8
mmol/l
0.10
308
2150
265
1737
2.31
16.19
5.2
4.9
30.1
34.9
g/l
24.68
255
1609
220
1336
2.28
16.14
6.3
3.5
2.3
2.4
mmol/l
3.05
202
1158
374
2871
2.94
15.96
17.5
8.1
123.4
79.5
u/l
11.66
360
2679
33
67
5.24
15.72
1.5
3.6
3.1
1.5
%
0.79
26
55
30
59
5.38
14.79
5.0
3.3
140.9
35.8
u/ml
1.58
30
59
243
1598
2.15
13.94
3.9
4.1
49.0
67.7
ng/l
0.29
215
1217
38
97
4.19
13.73
1.2
1.3
—
—
—
0
0
33
1029
0.27
13.56
1.3
1.6
15.6
20.6
nmol/l
1.57
27
865
26
53
5.15
12.31
1.2
1.6
—
—
—
0
0
28
62
4.75
12.06
1.0
1.2
—
—
—
0
0
326
2483
2.18
11.82
5.0
4.7
89.3
3995.7
e6/l
—
9
47
288
3516
0.48
11.29
3.7
5.0
6.0
6.1
mmol/l
0.21
240
3176
46
156
3.17
10.93
2.1
3.2
—
—
—
0
0
248
1753
1.94
10.51
5.3
4.3
—
—
—
0
0
18
30
6.21
10.47
1.2
1.7
—
—
—
0
0
243
1714
1.93
10.29
4.8
6.0
19.1
26.7
%
21.37
228
1591
98
1659
0.47
9.68
1.7
2.1
78.8
93.5
pmol/l
3.28
60
858
35
108
3.43
9.66
1.3
1.4
—
—
—
0
0
20
40
5.19
9.66
1.2
1.7
—
—
—
0
0
161
1007
1.94
9.64
4.4
4.2
0.0
0.0
estimate
0.50
63
323
69
1301
0.44
8.98
3.0
3.9
10.1
9.7
mg/mmol
0.04
41
822
20
43
4.82
8.91
1.2
2.1
—
—
—
0
0
265
3241
0.55
8.45
3.9
4.6
2.0
2.4
mu/l
0.54
228
2888
19
41
4.80
8.43
1.2
2.2
—
—
—
0
0
23
59
4.06
8.25
1.1
1.7
—
—
—
0
0
17
34
5.16
8.20
1.2
2.1
—
—
—
0
0
17
34
5.16
8.20
1.2
2.1
—
—
—
0
0
17
34
5.16
8.20
1.2
2.1
—
—
—
0
0
22
56
4.08
7.98
2.1
2.1
90.6
89.5
%
0.58
22
56
61
282
2.35
7.95
1.6
1.7
—
—
—
0
0
20
50
4.14
7.42
1.3
1.3
16481.5
32997.7
e6/l
0.64
15
29
23
66
3.62
7.08
1.1
1.7
—
—
—
0
0
12
20
6.14
6.94
1.3
1.8
—
—
—
0
0
12
20
6.14
6.94
1.2
1.8
—
—
—
0
0
40
162
2.61
6.90
2.0
1.8
—
—
—
0
0
32
116
2.90
6.79
1.2
1.6
—
—
—
0
0
399
3529
2.32
6.74
28.5
16.7
42.7
26.3
mg/l
13.77
377
2852
11
18
6.24
6.46
1.3
2.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
37
150
2.60
6.37
2.2
2.4
0.4
0.3
u/ml
0.52
28
81
23
73
3.27
6.10
1.1
1.6
—
—
—
0
0
108
676
1.79
6.05
1.8
1.9
—
—
—
0
0
191
1397
1.65
6.03
4.8
4.4
—
—
—
0
0
13
27
4.93
6.01
1.7
3.8
—
—
—
0
0
11
20
5.61
5.83
1.3
2.1
—
—
—
0
0
11
20
5.61
5.83
1.3
2.1
—
—
—
0
0
11
20
5.61
5.83
1.3
2.1
—
—
—
0
0
11
20
5.61
5.83
1.3
2.1
—
—
—
0
0
32
706
0.41
5.82
3.6
2.9
0.8
1.0
e6/l
0.24
22
420
10
17
6.00
5.65
1.3
2.3
—
—
—
0
0
10
17
6.00
5.65
1.3
2.3
—
—
—
0
0
13
29
4.59
5.54
1.2
1.6
—
—
—
0
0
100
1485
0.58
5.45
1.6
2.2
80.0
78.1
nmol/l
0.25
92
1294
32
684
0.43
5.35
1.1
1.2
1.0
1.1
u/ml
0.17
12
184
19
59
3.32
5.23
1.2
1.7
—
—
—
0
0
21
529
0.37
5.14
1.1
1.3
25.3
12.8
u/ml
—
6
194
34
150
2.37
4.94
1.9
1.7
—
—
—
0
0
23
545
0.39
4.90
1.0
1.3
50.5
42.9
iu/ml
—
7
161
8
7
11.61
4.80
1.6
1.6
—
—
—
0
0
215
2623
0.65
4.76
3.8
3.7
15.2
15.0
pmol/l
0.67
185
2330
13
36
3.69
4.23
1.4
1.4
—
—
—
0
0
36
668
0.50
4.01
3.8
3.1
0.7
1.7
e6/l
2.22
26
386
247
2872
0.68
3.74
29.9
20.6
15.2
13.8
%
21.97
241
2820
126
921
1.51
3.63
2.6
2.6
—
—
—
0
0
9
256
0.34
3.42
1.3
1.7
—
—
—
0
0
111
800
1.52
3.39
6.8
3.2
2.5
2.5
mmol/l
1.76
100
702
9
19
4.81
3.25
3.4
4.5
344.4
107.2
nmol/l
—
9
19
152
1182
1.44
3.14
2.0
2.1
162.4
295.8
u/l
1.11
140
1104
44
257
1.79
3.08
1.5
1.5
—
—
—
0
0
26
128
2.10
2.98
1.2
1.3
—
—
—
0
0
77
529
1.55
2.91
3.9
5.6
1.0
1.0
mmol/l
0.69
71
483
306
3372
0.70
2.90
29.1
15.6
78.9
74.5
ml/min/173m2
2.90
278
2809
13
48
2.76
2.74
1.1
1.6
—
—
—
0
0
42
251
1.74
2.74
3.0
3.7
2.6
1.9
mmol/l
0.49
37
189
8
19
4.27
2.69
1.5
2.1
—
—
—
0
0
13
50
2.65
2.55
1.1
1.6
—
—
—
0
0
13
50
2.65
2.55
1.1
1.6
—
—
—
0
0
13
50
2.65
2.55
1.1
1.6
—
—
—
0
0
13
50
2.65
2.55
1.5
1.1
22.7
12.1
u/l
1.11
13
39
13
50
2.65
2.55
1.1
1.6
—
—
—
0
0
18
361
0.48
2.52
1.1
1.4
—
—
—
0
0
398
3741
1.63
2.51
28.7
19.7
137.5
139.7
mmol/l
26.52
384
3643
8
21
3.86
2.47
1.5
1.9
—
15.8
—
0
10
13
51
2.60
2.46
1.1
1.6
—
—
—
0
0
118
1488
0.72
2.45
1.9
2.7
656.2
151.7
ug/l
4.92
105
1360
398
3747
1.61
2.42
28.6
19.8
4.0
4.0
mmol/l
1.89
385
3648
212
1810
1.33
2.29
4.5
4.1
0.0
0.0
estimate
0.50
74
326
54
364
1.55
2.24
2.3
3.1
65.2
66.1
g/l
0.33
49
331
9
29
3.15
2.23
1.4
1.5
—
—
—
0
0
74
993
0.69
2.17
2.8
3.0
339.5
8624.1
umol/l
4.81
65
844
175
1463
1.32
2.16
3.0
3.3
—
—
—
0
0
5
147
0.33
2.04
1.2
2.8
0.0
0.9
g/l
—
5
131
162
1356
1.31
1.94
2.5
3.2
1798.2
1568.8
ng/l
0.24
141
1179
53
373
1.48
1.82
2.3
2.7
4.0
6.7
ug/l
1.45
42
327
7
23
3.08
1.80
1.3
1.7
—
—
—
0
0
205
1785
1.28
1.78
5.6
5.5
0.0
0.0
estimate
0.00
71
339
76
980
0.73
1.74
2.8
3.3
1.6
0.8
ug/l
2.83
59
700
17
303
0.54
1.71
1.5
1.8
2.5
1.6
%
0.50
11
258
0
48
0.00
1.70
0.0
1.1
—
23.3
—
0
10
7
25
2.83
1.65
1.3
1.4
37.0
33.8
u/l
—
7
19
5
131
0.37
1.65
1.2
2.7
0.0
0.0
g/l
—
5
122
241
2153
1.26
1.64
3.0
3.3
108.8
51.9
u/l
2.46
220
1970
203
1785
1.25
1.56
4.3
4.1
0.0
0.0
estimate
0.00
72
340
6
142
0.41
1.55
1.0
1.0
—
—
—
0
0
16
86
1.89
1.52
1.3
1.5
—
—
—
0
0
0
45
0.00
1.50
0.0
1.0
—
—
—
0
0
65
494
1.37
1.49
5.7
7.4
5.2
5.1
kpa
0.23
60
476
247
2705
0.80
1.48
3.0
4.2
26.9
13.8
mm/h
10.43
213
2457
65
495
1.37
1.47
5.7
7.4
11.9
11.8
kpa
0.03
59
478
65
495
1.37
1.47
5.7
7.5
2.7
1.2
mmol/l
1.96
44
388
5
16
3.15
1.44
1.0
1.1
—
—
—
0
0
6
139
0.42
1.42
1.2
2.6
28.6
37.2
g/l
—
6
120
5
123
0.40
1.39
1.2
2.8
0.0
0.0
g/l
—
5
115
5
124
0.40
1.38
1.2
2.8
0.0
0.0
g/l
—
5
115
6
134
0.44
1.30
1.3
1.5
—
—
—
0
0
61
472
1.34
1.26
1.6
1.9
—
—
—
0
0
11
200
0.54
1.22
1.0
1.3
—
48.4
—
0
13
399
3849
1.37
1.18
40.0
24.5
3.9
4.4
e12/l
55.41
385
3729
0
34
0.00
1.16
0.0
1.0
—
2.8
—
0
10
399
3851
1.36
1.15
40.3
24.6
118.0
133.9
g/l
59.85
388
3785
95
791
1.26
1.15
5.0
4.5
1.0
1.0
kg/l
1.81
19
124
61
480
1.31
1.14
17.2
7.6
—
—
—
0
0
6
123
0.48
1.06
1.3
1.4
—
—
—
0
0
64
789
0.78
1.06
2.8
4.2
157.9
328.1
ng/l
1.01
49
676
9
161
0.55
0.99
1.1
2.5
11.3
10.5
g/l
—
9
139
0
30
0.00
0.97
0.0
1.2
—
2.1
—
0
12
0
31
0.00
0.96
0.0
1.8
—
—
—
0
0
0
31
0.00
0.96
0.0
1.2
—
94.4
—
0
5
0
32
0.00
0.95
0.0
1.0
—
485.9
—
0
19
0
32
0.00
0.95
0.0
1.0
—
44.1
—
0
17
287
3037
0.84
0.93
20.8
18.1
33.1
38.9
%
6.22
124
1935
6
28
2.16
0.92
1.5
1.4
—
—
—
0
0
6
28
2.16
0.92
1.0
1.2
—
—
—
0
0
6
28
2.16
0.92
1.5
1.4
—
—
—
0
0
387
3745
1.26
0.88
18.8
11.3
27.4
24.9
u/l
1.20
373
3592
120
1355
0.84
0.85
5.0
4.8
26.2
21.0
%
2.59
75
718
11
176
0.62
0.81
1.2
2.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
0
26
0.00
0.78
0.0
1.8
—
—
—
0
0
94
815
1.19
0.78
2.1
1.7
1359.0
1208.5
nmol/l
0.79
78
616
0
28
0.00
0.76
0.0
1.2
—
—
—
0
0
57
472
1.24
0.75
1.5
1.9
—
—
—
0
0
386
3748
1.23
0.75
34.4
20.1
79.2
83.0
umol/l
1.48
386
3748
19
133
1.45
0.75
1.2
4.7
46.4
115.8
mg/l
0.73
12
103
19
133
1.45
0.75
1.2
4.7
38.6
35.1
mg/l
0.07
12
106
67
787
0.82
0.74
1.5
1.7
2.2
1.4
mg/l
0.79
49
623
7
117
0.59
0.69
1.0
1.3
—
—
—
0
0
155
1688
0.87
0.67
7.0
5.7
20.9
2.9
ug/l
5.31
144
1493
11
70
1.59
0.65
1.0
1.3
—
—
—
0
0
6
101
0.59
0.63
1.7
1.7
—
—
—
0
0
0
20
0.00
0.60
0.0
1.4
—
—
—
0
0
28
223
1.27
0.54
3.5
3.4
25.6
24.9
mmol/l
0.31
28
216
7
108
0.64
0.49
1.1
1.7
—
—
—
0
0
122
1126
1.12
0.45
2.9
3.3
0.9
0.6
e6/l
0.77
108
860
7
51
1.38
0.44
2.4
1.3
—
—
—
0
0
13
172
0.75
0.41
1.2
1.2
52.9
139.1
iu/ml
—
6
61
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
62.8
—
0
16
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
32
378
0.83
0.41
1.4
1.4
—
—
—
0
0
0
17
0.00
0.40
0.0
3.5
—
—
—
0
0
0
17
0.00
0.40
0.0
3.5
—
—
—
0
0
10
135
0.73
0.36
1.2
1.3
—
—
—
0
0
6
41
1.47
0.36
6.0
2.3
—
3.8
—
0
9
48
426
1.14
0.34
2.4
3.1
9.8
9.1
umol/l
0.08
42
383
32
370
0.85
0.33
5.4
6.7
1.7
1.4
mmol/l
0.53
32
355
24
282
0.84
0.30
3.5
3.2
117.9
125.7
g/l
1.04
24
276
45
503
0.88
0.30
2.3
4.8
33.4
31.8
%
0.40
32
336
12
93
1.30
0.30
2.3
4.5
26.0
30.0
mg/l
—
5
61
31
269
1.16
0.30
2.1
2.3
3.7
12.4
nmol/l
6.30
26
234
16
194
0.82
0.28
2.4
3.9
24.1
24.3
mmol/l
0.04
16
174
54
592
0.90
0.27
20.3
26.3
1.2
1.3
inr
—
8
76
44
398
1.12
0.25
3.1
3.7
3.8
2.0
mmol/l
1.44
32
319
5
39
1.29
0.23
1.8
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
5
43
1.16
0.21
1.8
2.3
—
—
—
0
0
5
43
1.16
0.21
4.6
4.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
9.7
—
0
13
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
28
309
0.90
0.17
2.5
3.1
61.2
60.2
ml/min/173m2
—
8
129
6
76
0.79
0.15
1.5
1.4
—
—
—
0
0
6
76
0.79
0.15
1.5
1.4
—
—
—
0
0
14
121
1.16
0.15
1.4
1.6
—
111.4
—
0
7
43
401
1.08
0.15
3.1
3.7
5.8
5.7
kpa
0.18
43
387
7
89
0.78
0.14
1.6
2.6
286.9
201.1
%
—
7
84
51
538
0.94
0.12
6.4
6.8
102.3
104.2
mmol/l
1.72
51
523
10
85
1.18
0.12
1.2
1.5
—
—
—
0
0
20
216
0.92
0.08
3.0
2.5
0.8
0.7
%
1.26
20
211
91
885
1.04
0.08
1.5
1.8
426.1
5502495.7
pmol/l
0.50
75
727
6
74
0.81
0.07
1.0
1.2
1.3
12.5
e6/l
—
6
61
6
74
0.81
0.07
1.3
1.3
28.5
1573.0
e6/l
—
6
62
9
85
1.06
0.07
2.2
1.2
482.2
512.9
mg/l
—
9
79
33
342
0.96
0.04
3.6
2.9
4.4
4.3
kpa
0.20
33
328
104
1028
1.02
0.02
1.5
2.1
4.3
3.2
mg/l
1.87
94
891
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
112.0
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
9
99
0.91
0.00
1.1
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
8
0.00
0.00
0.0
3.1
—
135.5
—
0
8
9
99
0.91
0.00
1.1
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
1377.6
—
0
7
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
81.3
—
0
7
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
81.0
—
0
6
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_SECONDARY_NAS – Secondary malignant neoplasm of other and unspecified sites
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).